Plato Investment Management Ltd Takes $1.14 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Plato Investment Management Ltd acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, HoldingsChannel reports. The firm acquired 63,530 shares of the company’s stock, valued at approximately $1,144,000.

Other institutional investors have also added to or reduced their stakes in the company. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries during the first quarter valued at approximately $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $30,000. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Claro Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $52,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.75 on Friday. The firm’s 50-day moving average price is $17.84 and its 200-day moving average price is $17.20. Teva Pharmaceutical Industries Limited has a 1-year low of $8.64 and a 1-year high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.